Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect

Cannabinoids affect positive and negative affective experience and emotional perception, possibly by modulating limbic brain reactivity. In this double-blind crossover, placebo-controlled functional magnetic resonance imaging study in humans, an acute oral dose of ∆9-tetrahydrocannabinol (THC) attenuated subgenual anterior cingulate cortex (sgACC) reactivity during the induction of negative affect. This observation extends prior findings implicating a cortico-limbic, emotion-related central mechanism underlying cannabinoid function.

[1]  B. Gorzalka,et al.  The endocannabinoid system and the treatment of mood and anxiety disorders. , 2009, CNS & neurological disorders drug targets.

[2]  Chaogan Yan,et al.  5-HTTLPR Polymorphism Impacts Task-Evoked and Resting-State Activities of the Amygdala in Han Chinese , 2012, PloS one.

[3]  David A Lewis,et al.  Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. , 2006, Cerebral cortex.

[4]  D. Jasinski,et al.  Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man , 1971, Clinical pharmacology and therapeutics.

[5]  M. Posner,et al.  Cognitive and emotional influences in anterior cingulate cortex , 2000, Trends in Cognitive Sciences.

[6]  T. Wenger,et al.  Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study☆ , 2000, Peptides.

[7]  R. Murray,et al.  Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology , 2010, Neuropsychopharmacology.

[8]  D. Pizzagalli.  Frontocingulate Dysfunction in Depression: Toward Biomarkers of Treatment Response , 2011, Neuropsychopharmacology.

[9]  C. Schuster,et al.  'Hangover' effects the morning after marijuana smoking. , 1985, Drug and alcohol dependence.

[10]  A. Hariri,et al.  Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression. , 2010, Addictive behaviors.

[11]  B. Horwitz,et al.  Brain activity during transient sadness and happiness in healthy women. , 1995, The American journal of psychiatry.

[12]  A. Meyer-Lindenberg,et al.  5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.

[13]  K. Luan Phan,et al.  Functional Neuroanatomy of Emotion: A Meta-Analysis of Emotion Activation Studies in PET and fMRI , 2002, NeuroImage.

[14]  H. de Wit,et al.  Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. , 2002, Psychopharmacology.

[15]  W. Drevets,et al.  Functional neuroimaging studies of depression: the anatomy of melancholia. , 1998, Annual review of medicine.

[16]  L. Parsons,et al.  Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. , 1999, The American journal of psychiatry.

[17]  Guy M. Goodwin,et al.  Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues , 2006, Biological Psychiatry.

[18]  H. de Wit,et al.  Comparison of the subjective effects of Δ9-tetrahydrocannabinol and marijuana in humans , 2002, Psychopharmacology.

[19]  E. Uhlenhuth,et al.  Drug preference and mood in humans: Repeated assessment of d-amphetamine , 1981, Pharmacology Biochemistry and Behavior.

[20]  P. Lang.  International affective picture system (IAPS) : affective ratings of pictures and instruction manual , 2005 .

[21]  L E Hollister,et al.  Health aspects of cannabis. , 1986, Pharmacological reviews.

[22]  T. Cassano,et al.  Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Lozano,et al.  Deep Brain Stimulation for Treatment-Resistant Depression , 2005, Neuron.

[24]  D. Piomelli,et al.  The endocannabinoid system as a target for therapeutic drugs. , 2000, Trends in pharmacological sciences.

[25]  H. Mayberg.  Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. , 2003, British medical bulletin.

[26]  A. Mechelli,et al.  Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. , 2010, The international journal of neuropsychopharmacology.

[27]  P. Isaacson,et al.  Immunoproliferative small-intestinal disease. An immunohistochemical study. , 1989, The American journal of surgical pathology.

[28]  M. Angstadt,et al.  Cannabinoid Modulation of Amygdala Reactivity to Social Signals of Threat in Humans , 2008, The Journal of Neuroscience.

[29]  M. Herkenham,et al.  Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains , 1994, Neuroscience.

[30]  H. Wit,et al.  Responses to Oral Δ9-Tetrahydrocannabinol in Frequent and Infrequent Marijuana Users , 1999, Pharmacology Biochemistry and Behavior.

[31]  R. Turner,et al.  Characterizing Dynamic Brain Responses with fMRI: A Multivariate Approach , 1995, NeuroImage.

[32]  Wayne Hall,et al.  Adverse effects of cannabis , 1998, The Lancet.

[33]  P. McGuire,et al.  Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. , 2009, Archives of general psychiatry.

[34]  D. Yurgelun-Todd,et al.  Altered affective response in marijuana smokers: an FMRI study. , 2009, Drug and alcohol dependence.

[35]  D. Abrous,et al.  CB1 receptor deficiency decreases wheel-running activity: Consequences on emotional behaviours and hippocampal neurogenesis , 2010, Experimental Neurology.

[36]  A. Romano,et al.  The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. , 2009, International review of neurobiology.

[37]  Caroline F. Zink,et al.  Vasopressin Modulates Medial Prefrontal Cortex–Amygdala Circuitry during Emotion Processing in Humans , 2010, The Journal of Neuroscience.

[38]  Justin S. Feinstein,et al.  Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. , 2005, Archives of general psychiatry.

[39]  M. Raichle,et al.  Subgenual prefrontal cortex abnormalities in mood disorders , 1997, Nature.

[40]  M. Furey,et al.  Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression , 2008, Brain Structure and Function.

[41]  T. Hayase.  Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs , 2007, BMC Neuroscience.

[42]  Lisa Feldman Barrett,et al.  Functional grouping and cortical–subcortical interactions in emotion: A meta-analysis of neuroimaging studies , 2008, NeuroImage.

[43]  Marc Parmentier,et al.  Distribution of cannabinoid receptor messenger RNA in the human brain: An in situ hybridization histochemistry with oligonucleotides , 1992, Neuroscience Letters.

[44]  Philip K. McGuire,et al.  Modulation of effective connectivity by cognitive demand in phonological verbal fluency , 2006, NeuroImage.

[45]  K. Mackie,et al.  Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system , 1998, Neuroscience.